| Novartis Pharma Schweiz AG - Tasigna 50 mg, Kapseln | | 58007 | | 03 | | Tasigna 50 mg | | Kapseln | | L01EA03 | | | | 31.01.2018 | | |
| | Composition | | nilotinibum 50 mg ut nilotinibi hydrochloridum monohydricum, lactosum monohydricum 39.025 mg, crospovidonum, poloxamerum, silica colloidalis anhydrica, magnesii stearas, Kapselhülle: gelatina, E 171, E 172 (flavum), E 172 (rubrum), Drucktinte: lacca, E 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum, pro capsula. | | Packungsbestandteile | | Capsules | | | | Active Agent | Dose |
|---|
| Nilotinibum | 50 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| | | | | | | | | | | | | Ammoniae Solutio | 28 | | | | | | | | | color. | | | | color. | | Gelatina | | Kapselhülle | | | | Drucktinte | | Lactose Monohydrate | 39.025 mg | | | | | | | Per Centum | | | | Poloxamer | | | | | | | | Propylenglycol | | | | Silica Colloidalis Anhydrica | | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 005 | 120 | PR | PR | A | | No |
|
|
